Citizens JMP raised the firm’s price target on Enanta (ENTA) to $23 from $21 and keeps an Outperform rating on the shares. Enanta ended Q2 with cash of $193M and guiding to runway at least into fiscal 2028, and continues to advance its immunology pipeline, with the oral KIT and STAT6 candidates displaying good drug-like properties, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENTA:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue